Cardiology

Dr. Gregory Weiss weighs in on the ongoing debate over using the term provider to refer to doctors, which has recently been reignited on social media.

Investigators collect study data from lengthy questionnaires relating to diet and demographics, finding that a high glycemic index correlates to more adverse effects in patients.

TIMI Group investigators found the effects of dapagliflozin on cardiovascular risk in patients with diabetes were comparable in those with markers of CKD and those without markers of CKD at baseline.

An analysis of medical data from a major database in Taiwan suggests an inadequate response to DMARD therapy among patients with rheumatoid arthritis was associated with increased risk of acute coronary syndrome.

A deep-learning algorithm could help clinicians identify patients at increased risk of death from cardiovascular disease within the next 5 years based on the presence of vascular calcification.

Using data from nearly 1 million patients with type 2 diabetes in a commercial database, investigators provide a comprehensive of the impact race/ethnicity, gender, and income can have on the likelihood of receiving a prescription for SGLT2 inhibitors.

An expert discusses the continued need to clarify COVID-19-related thrombosis risks as well as ensuring patients receive the most accurate information.

Using data from the CARDIA study, UCSF investigators have determined the current ACC/AHA recommendations for physical activity may not be adequate for preventing hypertension throughout life.

Maria DeSancho, MD, talks personal experiences with patients, vaccine hesitancy, mRNA versus adenovirus technology, risks and types of thrombosis, and more.

Many patients have begun to engage in unhealthy lifestyle choices during the last 12 months.

A thrombosis expert details cerebral venous thrombosis, the side effect reported in a half-dozen women administered the Johnson & Johnson vaccine.

An analysis of the DECLARE-TIMI 58 trial indicates the cardiovascular benefit of dapagliflozin use in patients with diabetes was consistent regardless of baseline kidney function and suggests the effects could be independent of glucose reduction.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

A trial led by clinicians from Northwestern Medicine suggests the presence of ischemic leg symptoms could serve as a useful indicator for patients to help determine whether they will see a meaningful benefit from their walking program.

A case-controlled study of patients in the PREVEND study indicates HDL anti-inflammatory capacity could help identify patients at a greater risk of cardiovascular disease.

FDA, CDC recommended halting use of the one-shot vaccine at all federal sites.

An analysis of the CLARIFY registry is providing clinicians with further insight into the impact of diabetes in patients with chronic coronary syndromes, particularly the increased risk of stroke, myocardial infarction, and cardiovascular death.

HDL anti-inflammatory capacity was inversely associated with incident cardiovascular disease after the team used a fully adjusted model.

Our latest case report from Dr. Brady Pregerson features a man in his 40s presenting with shortness of breath and worsening leg edema. Can you determine the correct diagnosis?

Our latest case report from Dr. Brady Pregerson features a 20 y/o female brought to the emergency department by EMS for altered mental status. Check out the EKG and see if you can determine the diagnosis.

The risk of hypertension increased in pediatric patients with more complex surgery.

An analysis of the CLARIFY registry suggests patients with chronic coronary syndromes were 3 times more likely than the general population to have diabetes and these patients were at a greater risk of multiple adverse outcomes compared to their counterparts without diabetes.

A new study finds ambulatory telemedicine visits were exceptionally greater among minority communities through the pandemic.

An analysis of data from Cedars-Sinai medical centers suggests the shift to telemedicine during the pandemic led to a reduction in a number of diagnostic tests and medications prescribed when compared to rates of both during the pre-pandemic era.

An analysis of more than 4 million singleton births indicates children born at an early gestational age were at an increased risk of heart failure at multiple points throughout life when compared to their counterparts not considered preterm births.

An analysis of more than 8000 patients with HIV and hypertension suggests these patients may not be receiving the most efficacious antihypertensive agents and this could be placing these patients at increased risk of cardiovascular disease events or death.

The once-daily tablet is indicated for adult patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia

An analysis of the DAPA-HF trial indicates the impact of dapagliflozin were consistent across both men and women receiving the SGLT2 inhibitor.

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Dr. Nisha Parikh provides additional insight into the AHA's latest scientific statement, which highlights the need for greater attention and emphasis on the impact of adverse pregnancy outcomes on cardiovascular risk in women.